Laekna, Inc. (HKD) Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE111, LAE112, LAE113, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Ka mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. The company has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.

Laekna, Inc. (HKD) Active

3-2-467, 5 Xingbin Road, Yuyao, SH, CN

Stock Price HKD

Price Change

Last Dividend HKD

2105.HK's stock peer is 1167.HK (Jacobio Pharmaceuticals Group Co., Ltd.)

2105.HK's stock peer is 2157.HK (Lepu Biopharma Co., Ltd.)

2105.HK's stock peer is 2256.HK (Abbisko Cayman Limited)

2105.HK's stock peer is 2410.HK (TYK Medicines, Inc)

2105.HK's stock peer is 2616.HK (CStone Pharmaceuticals)

2105.HK's stock peer is 2617.HK (TransThera Sciences (Nanjing). Inc.)

2105.HK's stock peer is 6855.HK (Ascentage Pharma Group International)

2105.HK's stock peer is 6996.HK (Antengene Corporation Limited)

2105.HK's stock peer is 9966.HK (Alphamab Oncology)

2105.HK's stock peer is 9969.HK (InnoCare Pharma Limited)

Healthcare Biotechnology

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE111, LAE112, LAE113, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Ka mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. The company has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions